Why the study?
Does subcutaneous low-molecular-weight heparin administered at home improve outcomes in patients with proximal-vein thrombosis compared to intravenous unfractionated heparin administered in the hospital?
Does subcutaneous low-molecular-weight heparin administered at home improve outcomes in patients with proximal-vein thrombosis compared to intravenous unfractionated heparin administered in the hospital?
Subcutaneous low-molecular-weight heparin administered at home is a feasible, effective, and safe alternative to in-hospital intravenous unfractionated heparin for proximal-vein thrombosis.
Supports home LMWH for proximal-vein thrombosis; leaves open outcome superiority versus inpatient UFH.
In patients with proximal-vein thrombosis, treatment with low-molecular-weight heparin at home is feasible, effective, and safe.
No takes yet. Share an insight, caveat, or question.
Koopman et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: